{
  "image_filename": "table_p2_det_1_019.png",
  "image_path": "FlublokPI/extracted/figures/table_p2_det_1_019.png",
  "image_type": "Table",
  "page_number": 2,
  "block_id": "det_1_019",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "Table showing percentages of solicited local (pain, firmness/swelling, redness) and systemic (headache, fatigue, muscle pain, joint pain, nausea, shivers/chills, fever) adverse events for two vaccine groups: Flublok (N=972) and IIV3 (N=967), broken down by any, moderate, and severe events. does not support the claim because the data presented are safety and reactogenicity outcomes, with no measures of immune response breadth, cross-protection, or effectiveness in mismatch seasons. Note: Table only includes adverse event rates; immunogenicity or cross-protection data are not shown.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table showing percentages of solicited local (pain, firmness/swelling, redness) and systemic (headache, fatigue, muscle pain, joint pain, nausea, shivers/chills, fever) adverse events for two vaccine groups: Flublok (N=972) and IIV3 (N=967), broken down by any, moderate, and severe events.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the data presented are safety and reactogenicity outcomes, with no measures of immune response breadth, cross-protection, or effectiveness in mismatch seasons.",
    "confidence_notes": "Table only includes adverse event rates; immunogenicity or cross-protection data are not shown."
  }
}